|
|
|
|
“We need to pay attention that we aren’t running into a situation where tech companies sell black-box algorithms that determine parts of our lives.”
|
— Gerd Gigerenzer, director of the Harding Center for Risk Literacy at the University of Potsdam in Germany
|
|
|
|
|
|
|
|
SEBASTIAN GOLLNOW/DPA/ZUMA PRESS
|
|
|
|
That cup of Joe may not be as unhealthy as feared. A mug of America's favorite stimulant each day may not be bad for the heart after all, researchers reported. But the beverage did reduce the sleep of subjects in the randomized controlled trial. Read more.
|
|
|
For perimenopausal women, the brain fog is real--and temporary. About 60% of women in their 40s and early 50s report a decline in memory function, but their cognitive performance stays within a normal range and memory issues often resolve upon reaching menopause. Read more.
|
|
-
Drugs Are In the Works to Treat the Depression and Anxiety That Many Women Experience During Perimenopause (Read)
|
|
Contaminated eye drops linked to three deaths. Another six people who used the EzriCare and Delsam Pharma LLC’s Artificial Tears eye drops have experienced vision loss. The manufacturer recalled the drops last month. Read more.
|
|
-
EzriCare Eye Drops Recalled After CDC Linked Them to Infections (Read)
|
|
|
|
|
PETER BYRNE/ZUMA PRESS
|
|
|
|
Moderna Prices Its Covid Vaccine at $130 a Dose. The vaccine's price will be several times higher than the $15 to $26 a dose the federal government has paid, when sales shift to the commercial market later this year, sparking criticism from some Senators. Read more.
|
|
-
Pfizer Targeting Covid Vaccine Price of $110 to $130 a Dose (Read)
|
|
|
This newsletter was compiled by the WSJ’s Health & Science team. Follow us on Twitter @WSJHealth and @WSJScience. Email us by replying to this newsletter.
|
|
|
|
|